Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Trial of Low-Dose Selinexor (KPT-330) in Combination With Choline Salicylate (CS) for the Treatment of Patients With Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasms, or Multiple Myeloma

NCT04640779 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04640779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04640779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Trial of Low-Dose Selinexor (KPT-330) in Combination With Choline Salicylate (CS) for the Treatment of Patients With Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasms, or Multiple Myeloma
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
February 8, 2021
Completion date
November 19, 2025
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent histiocytic and dendritic cell neoplasm, recurrent hodgkin lymphoma, recurrent non-hodgkin lymphoma, recurrent plasma cell myeloma, refractory histiocytic and dendritic cell neoplasm, refractory hodgkin lymphoma, refractory non-hodgkin lymphoma, refractory plasma cell myeloma